Brief: Geneuro Postpones Phase 2 Multiple Sclerosis Trial

Geneuro SA

19/03/2020 06:48

March 19 (Reuters) - Geneuro SA  GNRO.PA :
    * GENEURO PHASE 2 MULTIPLE SCLEROSIS TRIAL UPDATE
    * TEMPORARY POSTPONEMENT OF PLANNED PHASE 2 TRIAL OF
TEMELIMAB IN
MULTIPLE SCLEROSIS AT KAROLINSKA INSTITUTET'S ACADEMIC
SPECIALIST CENTER (ASC), STOCKHOLM, SWEDEN
    * ONE-YEAR TRIAL WILL ENROLL PATIENTS WHOSE DISABILITY
PROGRESSES
WITHOUT RELAPSES
    * INITIATION OF TRIAL WILL NOW TAKE PLACE ONCE HOSPITALS
HAVE MORE
CAPACITIES FOR CLINICAL RESEARCH AND ARE ABLE TO ENSURE THAT MS
PATIENTS WILL NOT BE PUT AT RISK-CEO
    * WE MUST PUT FIGHT AGAINST COVID-19 AND SAFETY OF MS
PATIENTS
FIRST-CEO
    * POSTPONEMENT TO PRIORITIZE HEALTHCARE RESOURCES BEHIND
FIGHT OF
COVID-19 AND TO REDUCE RISK FOR MS PATIENTS

Source text for Eikon:  ID:nBw7h3SR4a 
Further company coverage:  GNRO.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))